
|Videos|October 18, 2017
Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma
Author(s)Sumanta Kumar Pal, MD
Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.
Advertisement
Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.
There are many drugs approved for patients with metastatic urothelial cancer. The highest levels of evidence are with pembrolizumab (Keytruda) and atezolizumab (Tecentriq) based on phase III data to support both regimens. Determining the sequencing of these agents remains a challenge to be investigated, according to Pal.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































